IDAHO FALLS, Idaho

爱达荷州，爱达荷福尔斯

,

，

July 2, 2026

2026年7月2日

/PRNewswire/ -- Radnostix, Inc. (OTCQB:

/美通社/ -- Radnostix公司（OTCQB：

INIS

国际核信息系统

) ('Radnostix' or the 'Company'), a leader in radioisotope production and nuclear medicine solutions, today announced the successful closing of its acquisition of key assets from Lucerno Dynamics, LLC, including the LARA® System technology platform, ELLEXA® Explorer software and associated intellectual property..

放射性同位素生产和核医学解决方案领域的领导者 Radnostix（以下简称“公司”）今日宣布，已成功完成从 Lucerno Dynamics, LLC 收购关键资产的交易，其中包括 LARA® 系统技术平台、ELLEXA® Explorer 软件及相关知识产权。

The product line was originally developed to identify, improve dosimetry of, and reduce the frequency of extravasations of IV administered radiopharmaceuticals. Recently, the product line expanded to include a Real-Time Visualization feature. Clinicians can now stop extravasations as they happen before they become a serious concern in the theranostics administration..

该产品线最初旨在识别、改善静脉注射放射性药物外渗的剂量测定并降低其发生频率。近期，该产品线扩展至包含实时可视化功能。临床医生现在能够在治疗诊断给药过程中，于外渗发生时立即阻止，防止其演变为严重问题。

The acquired portfolio of IP carries with it additional applications in uptake, dosimetry, quantification, and integration into auto-infusion drug delivery systems. This strategic acquisition enables Radnostix to develop the IP into new product  offerings in radiopharmaceutical and nuclear medicine applications by developing practical delivery and monitoring solutions for both new and existing market participants..

所收购的知识产权组合还带来了在摄取、剂量测定、定量以及整合至自动输注给药系统等方面的额外应用。此次战略性收购使 Radnostix 能够将该知识产权开发为放射性药物和核医学应用领域的新产品，为市场中的新老参与者提供实用的给药和监测解决方案。

'The Lucerno team have developed a broad  group of intellectual property and we are proud to carry the baton from here and expand the world of applications for their IP. I'd like to thank the team at Lucerno for their trust in our team to execute and deliver long term viability for their IP,' said Shahe Bagerdjian, CEO of Radnostix.

“Lucerno团队已开发出广泛的知识产权组合，我们自豪地接过接力棒，进一步拓展其知识产权的应用领域。我要感谢Lucerno团队信任我们，由我们来执行并确保其知识产权的长期可行性。”Radnostix首席执行官Shahe Bagerdjian表示。

'This acquisition marks a significant milestone in Radnostix's strategy to become a comprehensive solutions provider in the rapidly growing theranostics delivery & administration market. The LARA and ELLEXA technologies and IP will allow us to create innovative, user-friendly tools — drug uptake monitoring, dosimetry systems, and potentially pair with drug injection systems — that lower barriers to entry for clinics and improve safety and efficiency in radiopharmaceutical administration.

“此次收购标志着Radnostix在成为快速增长的诊疗一体化药物递送与管理市场综合解决方案提供商的战略进程中迈出了重要一步。LARA和ELLEXA的技术及知识产权将使我们能够开发出创新且用户友好的工具——包括药物摄取监测、剂量测定系统，并可能与药物注射系统联合使用——从而降低诊所的进入门槛，提高放射性药物管理的安全性和效率。”

We are excited to integrate these products and future capabilities into our growing device portfolio that better positions Radnostix as the go-to partner for RLT administration clinics.'.

我们很高兴将这些产品及未来功能整合到不断扩展的设备组合中，从而进一步巩固 Radnostix 作为放射性配体疗法（RLT）给药诊所首选合作伙伴的地位。

'I am extremely thankful to the Lucerno team, a dedicated group of nuclear medicine leaders and advisers, and our investors for their extensive work to develop this amazing patient safety product, the Lara System. Lara adds just 1-2 minutes to the radiopharmaceutical administration procedure and patients love the assurance that Lara provides,' said Ron Lattanze, CEO of Lucerno Dynamics.

“我衷心感谢Lucerno团队——一支由核医学领域领导者和顾问组成的敬业团队，以及我们的投资者，他们为开发这款卓越的患者安全产品Lara系统付出了大量努力。Lara系统仅使放射性药物给药过程增加1-2分钟，而患者非常喜爱Lara所提供的安全保障。”Lucerno Dynamics首席执行官Ron Lattanze表示。

He added, 'The Lara System and Ellexa software has been clinically proven in nearly 50,000 administrations in top centers across Australia, Singapore, Japan, Europe, and throughout the United States. We believe this product is a powerful tool to help improve patient safety in the rapidly growing and life-saving world of nuclear medicine and we look forward to supporting the Radnostix team to ensure every nuclear medicine patient experiences the confidence that comes from having the Lara System used during their radiopharmaceutical experience.'.

他补充道：“Lara系统和Ellexa软件已在澳大利亚、新加坡、日本、欧洲以及全美的顶尖中心进行了近5万次临床应用，其疗效得到了临床验证。我们相信，该产品是帮助提升核医学这一快速发展且拯救生命的领域患者安全性的有力工具。我们期待支持Radnostix团队，确保每一位接受放射性药物诊疗的核医学患者都能因使用Lara系统而充满信心。”

About Radnostix (formerly International Isotopes Inc.):

关于Radnostix（前身为International Isotopes Inc.）：

Radnostix, Inc. (formerly International Isotopes Inc.) (INIS), established in 1995, with its headquarters in Idaho Falls, ID, USA, manufactures a wide range of radioisotope-focused products. Radnostix manufactures and supplies generic sodium iodide I-131 radio-pharmaceutical drug product for hyperthyroidism and thyroid cancer.

Radnostix公司（前身为国际同位素公司）（INIS），成立于1995年，总部位于美国爱达荷州爱达荷福尔斯市，生产多种以放射性同位素为核心的产品。Radnostix公司制造并供应用于甲状腺功能亢进和甲状腺癌的通用型碘化钠I-131放射性药物产品。

Radnostix provides contract manufacturing of various drug products as well as radioisotope API supply for 3rd party theranostics clients. Radnostix manufactures and distributes a complete line of calibration and reference standards for nuclear pharmacies and SPECT/PET imaging systems as well as industrial calibration standards under its RadQual brand.

Radnostix 为第三方诊疗一体化客户提供各类药物产品的合同制造服务，以及放射性同位素活性药物成分（API）的供应。Radnostix 以其 RadQual 品牌，生产并分销面向核药房和 SPECT/PET 成像系统的完整校准与参考标准品系列，以及工业校准标准品。

For more information, visit .

更多信息，请访问。

www.radnostix.com

www.radnostix.com

.

。

Radnostix, Inc. (formerly International Isotopes Inc.) Safe Harbor Statement:

Radnostix, Inc.（前身为 International Isotopes Inc.）安全港声明：

Certain statements in this press release are 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including

本新闻稿中的某些陈述属于1933年《证券法》第27A条和1934年《证券交易法》第21E条所指的“前瞻性陈述”，包括

but not limited to, statements regarding the Company's current expected financial impact from the termination of the APA, the estimated value of the DUF6 Plant and related assets,

但不限于关于公司目前预期因终止APA而产生的财务影响、DUF6工厂及相关资产的估计价值的陈述，

statements with respect to the Company's future growth expectations. Information contained in such forward-looking statements is based on current expectations and is subject to change. These statements involve a number of risks, uncertainties and other factors that could cause actual results, performance, or achievements of Radnostix, Inc.

有关公司未来增长预期的陈述。此类前瞻性陈述中所载信息基于当前预期，并可能发生变化。这些陈述涉及许多风险、不确定性和其他因素，可能导致 Radnostix, Inc. 的实际结果、业绩或成就与预期不符。

to be materially different from any future results, performance or achievements of the Company expressed or implied by these forward-looking statements. Other factors, which could materially affect such forward-looking statements, can be found in the Company's filings with the Securities and Exchange Commission at.

与这些前瞻性陈述所明示或暗示的公司未来结果、表现或成就存在重大差异。其他可能对此类前瞻性陈述产生重大影响的因素，可在公司向美国证券交易委员会提交的文件中找到。

www.sec.gov

www.sec.gov

, including its Annual Report on Form 10-K for the year ended December 31, 2025. Investors, potential investors, and other readers are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements.

，包括其截至2025年12月31日止年度的10-K表格年度报告。我们敦促投资者、潜在投资者及其他读者在评估前瞻性陈述时仔细考虑这些因素，并提醒不要过度依赖此类前瞻性陈述。

The forward-looking statements made herein are only made as of the date of this press release and Radnostix, Inc. and the Company undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances..

本文所载前瞻性陈述仅截至本新闻稿发布之日有效，Radnostix, Inc. 及本公司不承担公开更新此类前瞻性陈述以反映后续事件或情况的义务。

Radnostix Contact:

Radnostix 联系方式：

[email protected]

[email protected]

radnostix.com

radnostix.com

SOURCE International Isotopes Inc.

来源：国际同位素公司

21

二十一

%

%

more press release views with

更多新闻稿浏览量，通过

Request a Demo

请求演示